Development Of ADX10059 Ended For Long-Term Use
Addex Pharmaceuticals announced that based on preliminary review of the unblinded data from study 206, it has terminated development of ADX10059 for chronic indications, including long term treatment of gastroesophageal reflux disease and migraine prophylaxis. In study 206 the incidence of alanine transaminase (ALT) levels greater than five times the upper limit of normal ( > 5xULN) levels was 6% (16 of 257 patients); however, bilirubin remained normal in all but one patient.
For the full story, Click Here
- Entereg approved to restore bowel function post surgery
- New Treatment Hope For People With Recurring Depression
- FDA OKs Nexium in children ages 1 to 11
- FDA nod to CV Therapeutics’ Ranexa for treatment of chronic angia
